Reuters news agency reported on Tuesday that Ukraine received its first batch of 500,000 doses of the AstraZeneca COVID-19 vaccine on 23 February 2021, allowing it to launch its delayed vaccine roll-out, starting with front-line medical workers and soldiers.
The President of Ukraine, Volodymyr Zelenskiy, tweeted: "We will start vaccination ASAP. We need to fight COVID together."
Ukraine's Health Minister, Maksym Stepanov, stated on Facebook: "Now we are urgently clearing the cargo through customs and the vaccine will immediately go to the regions."
Reportedly, Ukraine has lagged behind its neighbours in securing vaccines for its 41 million people, asking EU member states for help while refusing to buy the Sputnik V COVID-19 vaccine from Russia.
Ukraine had planned to launch mass vaccinations in mid-February 2021 through the global COVAX programme for poorer countries but the government said the roll-out was postponed due to a delay in delivery.
The current AstraZeneca doses were produced by the Serum Institute of India, and Ukraine approved the vaccine this week.
The health ministry said it had agreed to buy a total of 17 million doses of Indian-made vaccines, including 15 million doses of the Novavax shot.
So far, Ukraine has registered over 1.3 million COVID-19 cases and 25,309 deaths.
ABEC opens new manufacturing facility in Wilson, NC
4basebio announces expansion of DNA offering for personalised mRNA medicines
Rznomics reports advances in high-efficiency circRNA production in Nucleic Acids Research
EpiVax introduces AI-enhanced models for immunogenicity prediction
Pfizer and BioNTech granted FDA approval for XFG-adapted COVID-19 vaccine
4basebio announces strategic collaboration with Genezen
Charles River and Medigen collaborate on next-generation enterovirus vaccine development
Innorna Nominated for 2026 Prix Galien USA Best Startup Award
Sanofi's MenQuadfi receives EU approval for infants from six weeks
Evaxion to present three-year cancer vaccine data at ESMO Congress 2026
Evaxion presents new preclinical data on cytomegalovirus vaccine EVX-V1
Northwest Biotherapeutics presents on propensity score matching at BNOS 2026